PIIND PI Industries Q4 FY26 results (Jan–Mar 2026) and concall
P I Industries reported a resilient Q4 and full year FY26, with consolidated revenue of ₹6,713.7 crores and 25% EBITDA margins, despite a challenging global and domestic agrochemical market. The pharma business showed strong 40% growth, and new products are increasingly contributing to exports. The company is strategically investing in new growth platforms like NCEs, biologicals, and electronic chemicals, though these require longer gestation periods and have impacted asset turns.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 12.4%, net profit down 39.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,221 | 1,901 | 1,787 | 1,900 | 1,872 −16% | 1,376 −28% | 1,565 −12% |
| EBITDA | 628 | 512 | 456 | 519 | 541 −14% | 302 −41% | 337 −26% |
| Net profit | 508 | 373 | 330 | 400 | 409 −19% | 311 −17% | 200 −39% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.





